Novo Nordisk recently became the fourth company to ask FDA for guidance concerning whether patents on pre-filled drug delivery devices should be listed in the Orange Book. Novo markets several drug products available in pre-filled pen-injector systems, including insulin and growth hormone.[More...]
↧